Form 4: Artelo Biosciences Director Acquires Stock Options

Director Steven Kelly acquired stock options in Artelo Biosciences, Inc. on December 20, 2024.

Summary

• On December 20, 2024, Steven Kelly, a director of Artelo Biosciences, Inc., acquired stock options.
• The stock options grant him the right to buy 1,750 shares of common stock at an exercise price of $0.9476 per share.
• The options vest on the earlier of December 20, 2025, or the day before the next annual meeting of the Issuer's stockholders, contingent upon Kelly remaining a service provider to the company.
• The options expire on December 20, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to stock options, which is a common practice. The grant to a director could be seen as a slightly positive sign of confidence, but it's not a major event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning the interests of management with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of one year is fairly typical, although some companies may use different vesting periods or performance-based vesting criteria.
• The exercise price is set at $0.9476, which may be at or near the current market price of the stock at the time of the grant.

Key Dates

Keywords

stock options, director, ARTL, Artelo Biosciences, Form 4, beneficial ownership, securities